scholarly journals Remission of Recurrent Primary Intracranial Malignant Lymphoma after High-dose Intra-arterial Corticosteroid Administration and Intra-arterial Chemotherapy —Case Report—

1994 ◽  
Vol 34 (10) ◽  
pp. 700-703 ◽  
Author(s):  
Akira HARA ◽  
Yasuhiko KAKU ◽  
Yasuaki NISHIMURA ◽  
Noboru SAKAI ◽  
Hiromu YAMADA
Keyword(s):  
Case Report ◽  
Malignant Lymphoma ◽  
High Dose ◽  
Corticosteroid Administration

Primary malignant lymphoma of the trigeminal region treated with rapid infusion of high-dose MTX and radiation: case report and review of the literature

2003 ◽  
Vol 60 (4) ◽  
pp. 343-348 ◽  
Author(s):  
Manabu Kinoshita ◽  
Shuichi Izumoto ◽  
Satoru Oshino ◽  
Masahiro Nonaka ◽  
Shusuke Moriuchi ◽  
...  
Keyword(s):  
Case Report ◽  
Malignant Lymphoma ◽  
High Dose ◽  
Review Of The Literature ◽  
Rapid Infusion ◽  
Trigeminal Region

Primary Pituitary Malignant Lymphoma Was Difficult to Differentiate from Nonfunctioning Pituitary Adenoma: A Case Report

2016 ◽  
Vol 77 (S 02) ◽  
Author(s):  
Yuta Murakami ◽  
Shinya Jinguji ◽  
Yugo Kishida ◽  
Taku Sato ◽  
Tadashi Watanabe ◽  
...  
Keyword(s):  
Case Report ◽  
Pituitary Adenoma ◽  
Malignant Lymphoma ◽  
Nonfunctioning Pituitary Adenoma

scholarly journals The diagnosis of a giant cardiac malignant lymphoma in the right ventricle: a case report

2021 ◽  
Vol 8 (2) ◽  
pp. 1620-1626
Author(s):  
Jiafeng Yu ◽  
Xin Zhao ◽  
Yingfeng Liu ◽  
Qingwei Yan ◽  
Fei Miao
Keyword(s):  
Case Report ◽  
Right Ventricle ◽  
Malignant Lymphoma ◽  
The Right

scholarly journals ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution

2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii18-ii18
Author(s):  
Kiyonori Kuwahara ◽  
Shigeo Ohba ◽  
Kazuyasu Matsumura ◽  
Saeko Higashiguchi ◽  
Daijiro Kojima ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Adverse Events ◽  
Malignant Lymphoma ◽  
Survival Time ◽  
Progression Free Survival ◽  
Treatment Method ◽  
The Other ◽  
High Dose ◽  
Other Hand

Abstract Background: Although high dose-methotrexate therapy has been performed for primary central nervous system malignant lymphoma (PCNSL), R-MPV (rituximab, methotrexate (MTX), procarbazine and vincristine) therapy is currently the first line therapy for (PCNSL) in our hospital. This study examines the results of R-MPV therapy comparing with past treatment. Method/Subjects: Thirty-seven patients treated at our hospital from 2009 to 2020 were included. Overall survival time, progression free survival time, and toxicities were evaluated. Results: The average age of patients was 65.7 years. Patients included 21 males and 16 females. Thirty-six patients were diagnosed DLBCL by resected brain tumor tissues, and one was diagnosed DLBCL by vitreous biopsy. As initial treatment, rituximab±HD-MTX therapy (R±MTX group) was performed in 20 cases, HD-MTX therapy plus radiation (R±MTX+RT group) was performed in 12 cases, and RMPV therapy was performed in 5 cases (R-MPV group). Median OS of all cases was 69 months and median PFS was 38 months. Median OS was 69 months in R±MTX group and could not be calculated in R±MTX+RT, and R-MPV groups. Median PFS was 16 months and 56 months in R±MTX group and R±MTX+RT, respectively, and could not be calculated in the R-MPV group. Although the R-MPV group had a short follow-up period, the results were considered to be comparable to those of the R±MTX+RT group. On the other hand, grade 3/4 adverse events occurred in 50%, 25%, and 100%, respectively. Conclusion: R-MPV therapy may delay the timing of radiation and reduce the amount of radiation. On the other hand, the frequency of adverse events is high, and more strict management of treatment is required.

Refractory eosinophilic fasciitis successfully treated with infliximab: A case report

2021 ◽  
pp. 239719832110043
Author(s):  
Paulina Śmigielska ◽  
Justyna Czarny ◽  
Jacek Kowalski ◽  
Aleksandra Wilkowska ◽  
Roman J. Nowicki
Keyword(s):  
Case Report ◽  
Connective Tissue ◽  
Treatment Failure ◽  
Immunosuppressive Drugs ◽  
Unknown Etiology ◽  
High Dose ◽  
Eosinophilic Fasciitis ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.

scholarly journals COVID‐19 reinfection in a healthcare worker after exposure with high dose of virus: A case report

2021 ◽  
Vol 9 (6) ◽  
Author(s):  
Shahram Ahmadian ◽  
Hadis Fathizadeh ◽  
Saeid Shabestari Khiabani ◽  
Mohammad Asgharzadeh ◽  
Hossein Samadi Kafil
Keyword(s):  
Case Report ◽  
Healthcare Worker ◽  
High Dose

scholarly journals Nonepileptic Myoclonus in COVID-19: Case Report

2021 ◽  
pp. 194187442110043
Author(s):  
Henly Hewan ◽  
Annie Yang ◽  
Aparna Vaddiparti ◽  
Benison Keung
Keyword(s):  
Case Report ◽  
Critically Ill ◽  
Recovery Phase ◽  
Critically Ill Patient ◽  
High Dose ◽  
The Novel ◽  
Neurological Manifestations ◽  
Immune Mediated ◽  
Novel Coronavirus ◽  
Post Infectious

In late 2019, the novel coronavirus, SARS-CoV-2, and the disease it causes, COVID-19, was identified. Since then many different neurological manifestations of COVID-19 have been well reported. Movement abnormalities have been rarely described. We report here a critically ill patient with COVID-19 who developed generalized myoclonus during the recovery phase of the infection. Myoclonus was associated with cyclical fevers and decreased alertness. Movements were refractory to conventional anti-epileptic therapies. There was concern that myoclonus could be part of a post-infectious immune-mediated syndrome. The patient improved fully with a 4-day course of high-dose steroids. Our experience highlights a rare, generalized myoclonus syndrome associated with COVID-19 that may be immune-mediated and is responsive to treatment.

Primary malignant lymphoma of the breast mimicking breast carcinoma: A case report

1991 ◽  
Vol 21 (2) ◽  
pp. 244-248 ◽  
Author(s):  
Shigeo Shiiki ◽  
Sadanori Fuchimoto ◽  
Fumiyuki Inoue ◽  
Yasuaki Kamikawa ◽  
Akira Gouchi ◽  
...  
Keyword(s):  
Case Report ◽  
Breast Carcinoma ◽  
Malignant Lymphoma
Sign in / Sign up

Export Citation Format

Share Document